Thermo Fisher Scientific and Immundiagnostik announced a collaboration to develop novel mass spectrometry-based assays for qualitative and quantitative analysis of proteins and peptides. These shall be widely applicable in research and routine clinical analysis for the diagnosis of cardiovascular diseases and bone metabolism disorders.
To develop a sensitive, reliable, qualitative and quantitative assay of complex samples, antibody capabilities from Immundiagnostik are used to optimize sample preparation and to efficiently isolate low level analytes in complex mixtures. For quantitative analysis of small peptides, proprietary, high-throughput Mass Spectrometric Immunoassay (MSIA) technology from Thermo Fischer will be applied, as well as their TSQ Vantage Triple Quadrupole Mass Spectrometer. To measure post-translational modifications, the Orbitrap Elite high-resolution accurate mass spectrometer is used.
In addition, Immundiagnostik will utilize its academic and clinical network to identify diagnostic parameters, validate novel liquid chromatography-triple quadrupole mass spectrometry (LC-MS/MS) products, and develop new assays for commercial distribution.
- Thermo Fisher Scientific, Inc., Waltham, MA, USA
- Immundiagnostik AG, Bensheim, Germany
